FDMT:4D Molecular Therapeutics Inc Snapshot | Charting | News | Options
$10.07 NASDAQ 3:14p ET
July 18 '26 		4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population GlobeNewswire
Last  Change Exchange
Market data is delayed by at least 15 minutes.
Markets Portfolio
    Symbol Lookup
    Latest Story
    4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
     GlobeNewswire
    Full Story →

    Headline News
    4DMT Announces New Employment Inducement Grants
    4:04p ET July 17 '26 GlobeNewswire
    4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
    4:04p ET June 30 '26 GlobeNewswire
    4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
    8:00a ET June 29 '26 GlobeNewswire
    More News →
    Day  2.99%Week  8.37%Month  12.59%More Charting →
    July 24 '26. Markets Closed.
    Last $10.07
    Day change   2.99%$0.31
    Open $10.38
    Gap at open $0.00
    Previous close $10.38
    Trading volume 682,426
    10 Day avg vol. 701,052
    Shares out. 52.3Mil
    Market cap. $526.4Mil
    Trading activity Below Avg.
    Previous data from yesterday, July 23 '26.

    Historical Price Performance
    3 month   7.13% 
    6 month   26.35% 
    1 year   120% 
    2 year   45.63% 

    Earnings
    Previous 12m -$2.70
    Next 12m Estimate -$3.93
    P/E ratio --
    Revenue 88Mil

    Market data provided by News provided by


    This site is published in the United States for U.S. residents only. The services offered within this site are available exclusively through our U.S. Financial Advisors. Stifel Nicolaus Financial Advisors may only conduct business with residents of the state in which they are properly registered. The information on this website is not an offer to sell or a solicitation of an offer to buy, any security, nor shall any such security be offered or sold to any person in any jurisdiction in which such offer, solicitation, purchase or sale may not lawfully be made.
    Important Disclosures | Privacy Notice | HIPAA Policy | Use of Information Policy | Business Continuity | Canada Trade Matching Statement

    Stifel, Nicolaus & Co., Inc. Member NYSE, FINRA, and SIPC.
    Stifel Nicolaus Canada Inc., is a member of CIPF/FCPE and IIROC
    Copyright © 2026 All rights reserved.